Seattle biotech heavy-hitters emerge from stealth with $46M for next-gen migraine treatments (opens in new tab)

Vedana Therapeutics emerged from stealth with a $46M Series A. Led by local biotech veterans, the Seattle startup is developing next-gen, at-home migraine injections.